Allogene Therapeutics (ALLO) Stock Forecast & Price Target

Compare

1,566 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ALLO Analyst Ratings

Strong Buy

7 Buy

0 Hold

1 Sell

Based on 8 analysts giving stock ratings to

Allogene

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ALLO Stock 12 Month Forecast

Average Price Target

$9.17

▲(519.59% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Allogene Therapeutics in the last 3 months. The average price target is $9.17 with a high forecast of $14.00 and a low forecast of $7.00. The average price target represents a 519.59% change from the last price of $1.48.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","15":"$15","3.75":"$3.75","7.5":"$7.5","11.25":"$11.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.75,7.5,11.25,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.24,2.2215384615384615,3.2030769230769227,4.184615384615385,5.166153846153846,6.147692307692307,7.1292307692307695,8.11076923076923,9.092307692307692,10.073846153846153,11.055384615384614,12.036923076923076,13.018461538461539,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.24,1.85,2.46,3.0700000000000003,3.6799999999999997,4.29,4.9,5.51,6.12,6.73,7.34,7.95,8.56,{"y":9.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.24,1.6830769230769231,2.126153846153846,2.569230769230769,3.012307692307692,3.455384615384615,3.8984615384615386,4.341538461538462,4.7846153846153845,5.227692307692307,5.67076923076923,6.113846153846153,6.556923076923077,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.72,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.13,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.95,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.69,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$14.00

Average Price Target$9.17

Lowest Price Target$7.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Robert Burns

H.C. Wainwright

Buy

440.54%

Upside

Reiterated

11/10/25

Allogene Therapeutics (ALLO) Receives a Buy from H.C. Wainwright

Sami Corwin

William Blair

―

Buy

―

Reiterated

11/07/25

Analysts Offer Insights on Healthcare Companies: Evolent Health (NYSE: EVH) and Allogene Therapeutics (NASDAQ: ALLO)

Biren Amin

Piper Sandler

Buy

372.97%

Upside

Reiterated

11/07/25

Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (NASDAQ: ALLO), NeurAxis, Inc. (NYSE MKT: NRXS) and Celcuity (NASDAQ: CELC)

John Newman

Canaccord Genuity

$14

Buy

845.95%

Upside

Reiterated

11/07/25

Positive Outlook for Allogene Therapeutics: Buy Rating Backed by Promising Pipeline Advancements and Strong Financial PositionWe await initial biomarker and clinical proof-of-concept data. Allogene is also testing a lymphodepletion-free treatment regimen, which could allow for better tolerability and easier usage by physicians. Expect futility analysis 1H26 for cema-cel in 1L DLBCL consolidation We look for a positive futility analysis 1H26 for cema-cel from despite stoppage for the ALLO-647 arm earlier this year due to a patient death. Allogene believes that a 30% difference in mrd- conversion rate between the active and control arms would be meaningful here. We continue to believe that utilizing cema- cel in mrd+ patients after 1L treatment will ultimately improve disease-free survival vs watchful waiting.

Asthika Goonewardene

Truist Financial

$10

Buy

575.68%

Upside

Reiterated

11/07/25

Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (NASDAQ: ALLO), Halozyme (NASDAQ: HALO) and Progyny (NASDAQ: PGNY)

Matthew Biegler

Oppenheimer

Buy

372.97%

Upside

Reiterated

11/06/25

Allogene Therapeutics (ALLO) Gets a Buy from Oppenheimer

Luca Issi

RBC Capital

Buy

508.11%

Upside

Reiterated

11/06/25

RBC Capital Remains a Buy on Allogene Therapeutics (ALLO)

Brian Cheng

J.P. Morgan

―

Sell

―

Downgraded

10/14/25

Allogene Therapeutics (ALLO) was downgraded to a Sell Rating at J.P. Morgan

William Pickering

Bernstein

―

Hold

―

Reiterated

08/22/25

Allogene Therapeutics (ALLO) Gets a Hold from Bernstein

Reni Benjamin

Citizens JMP

―

Hold

―

Reiterated

08/20/25

Allogene Therapeutics (ALLO) Receives a Hold from Citizens JMPCitizens JMP analyst Reni Benjamin reiterated a Market Perform rating on Allogene (NASDAQ: ALLO).

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

08/14/25

Analysts Are Bullish on Top Healthcare Stocks: Allogene Therapeutics (ALLO), Medios AG (MEDOF)

Jack Allen

Robert W. Baird

$9→$7

Buy

372.97%

Upside

Reiterated

08/05/25

Allogene Therapeutics (ALLO) Receives a Buy from Robert W. BairdBaird analyst Jack Allen lowered the price target on Allogene (NASDAQ: ALLO) to $7.00 (from $9.00) while maintaining a Outperform rating.

Samantha Semenkow

Citi

Buy

170.27%

Upside

Reiterated

06/02/25

Citi Keeps Their Buy Rating on Allogene Therapeutics (ALLO)

Michael Yee

Jefferies

Buy

440.54%

Upside

Reiterated

05/13/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: GlaxoSmithKline (LSE: GB:GSK), Sartorius Stedim Biotech (LSE: GB:0RG8) and Allogene Therapeutics (NASDAQ: ALLO)

Benjamin Burnett

Wells Fargo

Hold

170.27%

Upside

Reiterated

03/17/25

Stifel Nicolaus Keeps Their Hold Rating on Allogene Therapeutics (ALLO)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Robert Burns

H.C. Wainwright

Buy

440.54%

Upside

Reiterated

11/10/25

Allogene Therapeutics (ALLO) Receives a Buy from H.C. Wainwright

Sami Corwin

William Blair

―

Buy

―

Reiterated

11/07/25

Analysts Offer Insights on Healthcare Companies: Evolent Health (NYSE: EVH) and Allogene Therapeutics (NASDAQ: ALLO)

Biren Amin

Piper Sandler

Buy

372.97%

Upside

Reiterated

11/07/25

Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (NASDAQ: ALLO), NeurAxis, Inc. (NYSE MKT: NRXS) and Celcuity (NASDAQ: CELC)

John Newman

Canaccord Genuity

$14

Buy

845.95%

Upside

Reiterated

11/07/25

Asthika Goonewardene

Truist Financial

$10

Buy

575.68%

Upside

Reiterated

11/07/25

Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (NASDAQ: ALLO), Halozyme (NASDAQ: HALO) and Progyny (NASDAQ: PGNY)

Matthew Biegler

Oppenheimer

Buy

372.97%

Upside

Reiterated

11/06/25

Allogene Therapeutics (ALLO) Gets a Buy from Oppenheimer

Luca Issi

RBC Capital

Buy

508.11%

Upside

Reiterated

11/06/25

RBC Capital Remains a Buy on Allogene Therapeutics (ALLO)

Brian Cheng

J.P. Morgan

―

Sell

―

Downgraded

10/14/25

Allogene Therapeutics (ALLO) was downgraded to a Sell Rating at J.P. Morgan

William Pickering

Bernstein

―

Hold

―

Reiterated

08/22/25

Allogene Therapeutics (ALLO) Gets a Hold from Bernstein

Reni Benjamin

Citizens JMP

―

Hold

―

Reiterated

08/20/25

Allogene Therapeutics (ALLO) Receives a Hold from Citizens JMPCitizens JMP analyst Reni Benjamin reiterated a Market Perform rating on Allogene (NASDAQ: ALLO).

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

08/14/25

Analysts Are Bullish on Top Healthcare Stocks: Allogene Therapeutics (ALLO), Medios AG (MEDOF)

Jack Allen

Robert W. Baird

$9→$7

Buy

372.97%

Upside

Reiterated

08/05/25

Samantha Semenkow

Citi

Buy

170.27%

Upside

Reiterated

06/02/25

Citi Keeps Their Buy Rating on Allogene Therapeutics (ALLO)

Michael Yee

Jefferies

Buy

440.54%

Upside

Reiterated

05/13/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: GlaxoSmithKline (LSE: GB:GSK), Sartorius Stedim Biotech (LSE: GB:0RG8) and Allogene Therapeutics (NASDAQ: ALLO)

Benjamin Burnett

Wells Fargo

Hold

170.27%

Upside

Reiterated

03/17/25

Stifel Nicolaus Keeps Their Hold Rating on Allogene Therapeutics (ALLO)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Allogene Therapeutics

1 Month

xxx

Success Rate

8/17 ratings generated profit

Average Return

-2.66%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 47.06% of your transactions generating a profit, with an average return of -2.66% per trade.

3 Months

xxx

Success Rate

8/17 ratings generated profit

Average Return

-4.14%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 47.06% of your transactions generating a profit, with an average return of -4.14% per trade.

1 Year

John NewmanCanaccord Genuity

Success Rate

8/25 ratings generated profit

Average Return

-19.89%

reiterated a buy rating last month

Copying John Newman's trades and holding each position for 1 Year would result in 32.00% of your transactions generating a profit, with an average return of -19.89% per trade.

2 Years

xxx

Success Rate

4/16 ratings generated profit

Average Return

-33.29%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 25.00% of your transactions generating a profit, with an average return of -33.29% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALLO Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ALLO has received 7 Buy Ratings, 13 Hold Ratings, and 2 Sell Ratings. ALLO average Analyst price target in the past 3 months is 9.17.

Each month's total comprises the sum of three months' worth of ratings.

ALLO Financial Forecast

ALLO Earnings Forecast

Next quarter’s earnings estimate for ALLO is -$0.22 with a range of -$0.42 to -$0.18. The previous quarter’s EPS was -$0.19. ALLO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ALLO has Performed in-line its overall industry.

ALLO Sales Forecast

Next quarter’s sales forecast for ALLO is $2.00K with a range of $0.00 to $20.00K. The previous quarter’s sales results were $0.00. ALLO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ALLO has Performed in-line its overall industry.

ALLO Stock Forecast FAQ

What is ALLO’s average 12-month price target, according to analysts?

Based on analyst ratings, Allogene Therapeutics’s 12-month average price target is 9.17.

What is ALLO’s upside potential, based on the analysts’ average price target?

Allogene Therapeutics has 519.59% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ALLO a Buy, Sell or Hold?

Allogene Therapeutics has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 1 sell ratings.

What is Allogene Therapeutics’s price target?

The average price target for Allogene Therapeutics is 9.17. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $14.00 ,the lowest forecast is $7.00. The average price target represents 519.59% Increase from the current price of $1.48.

What do analysts say about Allogene Therapeutics?

Allogene Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of ALLO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Allogene Therapeutics (ALLO) Stock Forecast & Price Target

ALLO Analyst Ratings

ALLO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Allogene Therapeutics

ALLO Analyst Recommendation Trends

ALLO Financial Forecast

ALLO Earnings Forecast

ALLO Sales Forecast

ALLO Stock Forecast FAQ

Detailed List of Analyst Forecasts